COMPARISON OF A NOVEL, LABEL-FREE, AND REAL-TIME CELL BASED SYSTEM (XCELLIGENCE) WITH A CONVENTIONAL VIABILITY ASSAY (XTT) TO DETERMINE THE ANTI-PROLIFERATIVE EFFECT OF AT-101 IN HUMAN BREAST CANCER CELLS